APLAR Journal of Rheumatology Template
Write in a clean editor, then format for APLAR Journal of Rheumatology in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the APLAR Journal of Rheumatology format
APLAR Journal of Rheumatology is a peer-reviewed journal published by Wiley, covering Systemic Lupus Erythematosus Research, Rheumatoid Arthritis Research and Therapies, Autoimmune and Inflammatory Disorders Research.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." APLAR Journal of Rheumatology 12 (3): 45–58.
Formats any DOI in APLAR Journal of Rheumatology style. No sign-up. |
| Publishes research in | Systemic Lupus Erythematosus Research Rheumatoid Arthritis Research and Therapies Autoimmune and Inflammatory Disorders Research Spondyloarthritis Studies and Treatments Musculoskeletal Disorders and Rehabilitation |
| ISSN | 0219-0494 |
| h-index | 21 |
| i10-index | 50 |
| Total citations | 2,271 |
| Top institutions publishing here | Center for Rheumatology |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in APLAR Journal of Rheumatology per year
Citation impact of APLAR Journal of Rheumatology by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in APLAR Journal of Rheumatology
Abstract Tumor necrosis factor‐alpha (TNF‐α) is a proinflammatory cytokine that plays a pivotal role in regulating the inflammatory response in rheumatoid arthritis (RA). Although it is controversial whether TNF‐α genes are associated with RA susceptibility, they are well known to mediate RA pathogenesis. We review in depth the history, formation and biological action, TNF receptor,…
Abstract Objective: Adalimumab is a fully human, monoclonal, antitumour necrosis factor antibody approved for the treatment of rheumatoid arthritis (RA) in more than 60 countries. We investigated the efficacy and safety of 40 mg every‐other‐week (eow) subcutaneous injections of adalimumab with methotrexate (MTX) versus placebo with MTX in Korean patients with RA with insufficient responses…
Abstract Aims: Hip fracture is frequently studied to reflect osteoporosis related fractures. The aim of this study was to look at ethnic differences in the incidence of hip fractures between the three races in Malaysia. Methods: This was a retrospective study performed for the years 1996 and 1997. Data from hospitals treating hip fractures in…
Abstract Aim: To report the efficacy and safety of infliximab in the treatment of active rheumatoid arthritis (RA) in Chinese patients. Methods: This is a multicentre double‐blind placebo controlled study. Patients with active RA despite being on a stable dose of methotrexate were randomly assigned to receive either infliximab 3 mg/kg body weight or placebo…